Bibliography
- TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666.
- SILVER RM, MILLER KS, KINSELLA MB, SMITH EA, SCHABEL SI: Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. (1990) 88(5):470-476.
- KOWAL-BIELECKA O, KOWAL K, ROJEWSKA J et al.: Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann. Rheum. Dis. (2005) 64(9):1343-1346.
- YIANNOPOULOS G, PASTROMAS V, ANTONOPOULOS I et al.: Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol. Int. (2006) 27(4):357-361.
- BERETTA L, CARONNI M, RAIMONDI M et al.: Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre Clin. Rheumatol. (2006) 26(2):168-172.
- WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. (2000) 132(12):947-954.
- LIOSSIS SN, BOUNAS A, ANDONOPOULOS AP: Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) (2006) 45(8):1005-1008.